HPV and cancer;Cancer et infection à papillomavirus humain

Bulletin du Cancer

Volumn 92, Issue 1, 2005, Pages 59-64

  Spano, Jean Philippe ^a   Marcelin, Anne Genevieve ^a   Carcelin, Guislaine ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cancer; Human papillomavirus

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS DNA;

ANUS CANCER; CANCER; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; GENOTYPE; HEAD AND NECK CANCER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNITY; LUNG CANCER; MOUTH CANCER; PATHOGENESIS; REVIEW; UTERINE CERVIX CANCER; VAGINA CANCER; VERRUCA VULGARIS; VIRUS CLASSIFICATION; VIRUS LOAD; VULVA CANCER; WART VIRUS; CELLULAR IMMUNITY; CLASSIFICATION; FEMALE; GENETICS; IMMUNOLOGY; MALE; NEOPLASM; PAPILLOMA VIRUS; VIROLOGY; VIRUS INFECTION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; MALE; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS;

EID: 13744249374     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Ortholan C, Francois E, Gerard JP. Lésions préné oplasiques et cancer du canal. Bull Cancer 2003; 90: 405-11.
2. Palefsky JM, Holly EA. Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 2003; 31: 41-6.
3. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. j Infect Dis 2004; 189: 686-98.
4. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004; 96: 449-55.
5. Einstein MH, Kadish AS. Anogenital neoplasia in AIDS. Curr Opin Oncol 2004; 16: 455-62.
6. Graflund M, Sorbe B, Sigurdardottir S, Karlsson M. HPV-DNA, vascular space invasion, and their impact on the clinical outcome in early-stage cervical carcinomas. Int J Gynecol Cancer 2004; 14: 896-902.
7. Yang HJ, Liu VW, Tsang PC, et al. Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. Int J Gynecol Cancer 2004; 14: 903-10.
8. USPHS. USPHS/ISDA. Guidelines for the prevention of opportunistic infections in persons Infected with human immunodeficiency virus 1997. Report No46 (NoRR-12. 1997.
9. Horster S. Is anal carcinoma a HAART-related problem? Eur J Med Res 2003; 8: 142-6.
10. Roka S, Rasoul-Rockenschaub S, Roka J, Kirnbauer R, Muhlbacher F, Salat A. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 2004; 17: 366-9.
11. Conley LJ, Ellerbrock TV, Bush TJ, Chiasson MA, Sawo D, Wright TC. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet 2002; 359: 108-13.
12. Reidy PM, Dedo HH, Rabah R, Field JB, Mathog RH, Gregoire L, et al. Integration of human papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope 2004; 114: 1906-9.
13. Spano JP, Faivre S. Tumeurs malignes non associées au VIH: pronostic et traitement. Bull Cancer 2003; 90: 413-8.
14. Mork J, Lie KL, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
15. Hemminki K, Dong C, Frisch M. Tonsillar and other upper aerodigestive tract cancer among cervical cancer patient and their husbands. Eur J Cancer Prev 2000; 9: 433-7.
16. Dahlgren L, Dahlstrand HM, Lindquist D, et al. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int J Cancer 2004; 112: 1015-9.
17. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004; 15: 1428-36.
18. McGlennen RC. Human papillomavirus oncogenesis. Clin Lab Med 2000; 20: 383-406.
19. Array I, Tyring SK. Status of local cellular immunity in interferon-responsive and non responsive human papillomavirus-associated lesions. Sex Trans Dis 1996; 23: 475-80.
20. Ferenczy A, Coutlee F, Franco E, Hankins C. Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. Can Med Assoc J 2003; 169: 431-4.
21. Hagensee ME,Cameron JE, Leigh JE, Clark RA. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 2004; 328: 57-63.
22. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer 2004; 112: 854-9.
23. Lefevre J, Hankins C, Money D, Rachlis A, Pourreaux K, Coutlee F. Human papillomavirus type 16 viral load is higher in human immunodeficiency virus-seropositive women with high-grade squamous intraepithelial lesions than in those with normal cytology smears. J Clin Microbiol 2004; 42: 2212-5.
24. Heard I, Palefsky JM, Kazatchkine MD. The impact of HIV antiviral therapy on human papillomavirus (HPV) infections and HPV-related diseases. Antivir Ther 2004; 9: 13-22.
25. Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ, Wright TC. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-9.
26. Bartholomew JS, Stacey SN, Coles B, Burt DJ, Arrand JR, Stern PL. Identification of a naturally processed HLA A0201-restricted viral peptide from cells expressing human papillomavirus type 16 E6 oncoprotein. Eur J Immunol 1994; 24: 3175-9.
27. Bourgault Villada I, Beneton N, Bony C, Connan F, Monsonego J, Bianchi A, et al. Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. Eur J Immunol 2000; 30: 2281-9.
28. Ressing ME, Sette A, Brandt RM, Ruppert J, Wentworth PA, Hartman M, et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol 1995; 154: 5934-43.
29. Mandic A, Vujkov T. Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future? Ann Oncol 2004; 15: 197-200.
30. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996; 347: 1523-7.
31. Maiman M. Management of cervical neoplasia in human immunodeficiency virus-infected women. J Natl Cancer Inst Monogr 1998: 43-9.
32. Massad LS, Ahdieh L, Banning L, Minkoff H, Greenblatt RM, Watts H, et al. Evolution of cervical abnormalities among women with HIV-1: evidence from surveillance cytology in the women's interagency HIV study. J Acquir Immune Defic Syndr 2001; 27: 432-42.
33. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003; 12: 638-42.
34. Minkoff H, Ahdieh L, Massad LS, Anastos K, Watts DH, Melnick S, et al. The effect of highly active antiretroviral therapy on cervical cytologic changes associated with oncogenic HPV among HIV-infected women. AIDS 2001; 15: 2157-64.
35. Lillo FB, Ferrari D, Veglia F, Origoni M, Grasso MA, et al. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus-infected women: effect of highly active antiretroviral therapy. J Infect Dis 2001; 184: 547-51.
36. Shuman P, Ohmit SE, Klein RS, et al. Longitudinal study of cervical squamous incraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003; 188: 128-36.
37. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004; 31: 96-9.
38. Studenstsov YY, Schiffman M, Strickler HD, et al. Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol 2002; 40: 175:-60.
39. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 2004; 13: 110-6.
40. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV16 virus-like particles. J Infect Dis 2002; 186: 737-42.
41. Heim K, Widschwendter A, Pirschner G, et al. Antibodies to human papillomavirus 16 L1 virus-like particles as an independant prognostic marker in cervical cancer. Am J Obstet Gynecol 2002; 186: 705-11.
42. Hopfi R, Petter A, Thaler P, et al. High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis 2003; 3: 6-11.